Suppr超能文献

在预后分层组中进行的遗传改变分析表明,TP53 和 ARID1A 是肝内胆管癌临床不良表现的标志物。

Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.

机构信息

ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.

Department of Diagnostics and Public Health, Section of Anatomical Pathology, University and Hospital Trust of Verona, Verona, Italy.

出版信息

Sci Rep. 2018 May 8;8(1):7119. doi: 10.1038/s41598-018-25669-1.

Abstract

The incidence and mortality rates of intrahepatic cholangiocarcinoma have been rising worldwide. Few patients present an early-stage disease that is amenable to curative surgery and after resection, high recurrence rates persist. To identify new independent marker related to aggressive behaviour, two prognostic groups of patient were selected and divided according to prognostic performance. All patients alive at 36 months were included in good prognostic performers, while all patients died due to disease within 36 months in poor prognostic performers. Using high-coverage target sequencing we analysed principal genetic alterations in two groups and compared results to clinical data. In the 33 cases included in poor prognosis group, TP53 was most mutated gene (p = 0.011) and exclusively present in these cases. Similarly, ARID1A was exclusive of this group (p = 0.024). TP53 and ARID1A are mutually exclusive in this study. Statistical analysis showed mutations in TP53 and ARID1A genes and amplification of MET gene as independent predictors of poor prognosis (TP53, p = 0.0031, ARID1A, p = 0.0007, MET, p = 0.0003 in Cox analysis). LOH in PTEN was also identified as marker of disease recurrence (p = 0.04) in univariate analysis. This work improves our understanding of aggressiveness related to this tumour type and has identified novel prognostic markers of clinical outcome.

摘要

肝内胆管细胞癌的发病率和死亡率在全球范围内呈上升趋势。很少有患者表现出早期疾病,适合根治性手术,而且在切除后,高复发率仍然存在。为了确定与侵袭性行为相关的新的独立标志物,根据预后表现选择了两组预后患者,并进行了分组。所有在 36 个月时存活的患者均归入预后良好组,而所有在 36 个月内死于疾病的患者归入预后不良组。使用高覆盖靶向测序,我们分析了两组患者的主要遗传改变,并将结果与临床数据进行比较。在预后不良组的 33 例患者中,TP53 是突变频率最高的基因(p=0.011),且仅存在于这些患者中。同样,ARID1A 也仅存在于该组中(p=0.024)。在本研究中,TP53 和 ARID1A 是互斥的。统计分析显示,TP53 和 ARID1A 基因突变以及 MET 基因扩增是预后不良的独立预测因子(TP53,p=0.0031;ARID1A,p=0.0007;MET,p=0.0003,在 Cox 分析中)。PTEN 的 LOH 也被确定为疾病复发的标志物(p=0.04,在单因素分析中)。这项工作提高了我们对这种肿瘤类型侵袭性的理解,并确定了新的临床预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/371d/5940669/7b7058efe477/41598_2018_25669_Fig1_HTML.jpg

相似文献

2
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.
5
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
PLoS One. 2014 Dec 23;9(12):e115383. doi: 10.1371/journal.pone.0115383. eCollection 2014.
6
Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients.
Updates Surg. 2020 Mar;72(1):119-128. doi: 10.1007/s13304-020-00718-5. Epub 2020 Feb 4.
7
Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.
World J Gastroenterol. 2016 Jul 7;22(25):5814-21. doi: 10.3748/wjg.v22.i25.5814.
8
Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with poor prognosis.
Cancer Lett. 2002 Jul 26;181(2):215-22. doi: 10.1016/s0304-3835(02)00052-6.
9
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
Gynecol Oncol. 2012 Sep;126(3):466-73. doi: 10.1016/j.ygyno.2012.05.012. Epub 2012 May 15.
10
Mutational landscape of intrahepatic cholangiocarcinoma.
Nat Commun. 2014 Dec 15;5:5696. doi: 10.1038/ncomms6696.

引用本文的文献

1
SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025).
Clin Transl Oncol. 2025 May 30. doi: 10.1007/s12094-025-03916-y.
2
A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier.
Clin Cancer Res. 2024 Aug 15;30(16):3499-3511. doi: 10.1158/1078-0432.CCR-24-0657.
3
Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.
Cancer Med. 2023 Aug;12(16):16716-16733. doi: 10.1002/cam4.6294. Epub 2023 Jun 27.
6
Role of molecular genetics in the clinical management of cholangiocarcinoma.
ESMO Open. 2022 Jun;7(3):100505. doi: 10.1016/j.esmoop.2022.100505. Epub 2022 Jun 10.
8
The Curious Case of the HepG2 Cell Line: 40 Years of Expertise.
Int J Mol Sci. 2021 Dec 4;22(23):13135. doi: 10.3390/ijms222313135.
10
Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.
Front Oncol. 2021 Jun 25;11:693295. doi: 10.3389/fonc.2021.693295. eCollection 2021.

本文引用的文献

1
Comprehensive Analysis of Hypermutation in Human Cancer.
Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.
3
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Cancer Discov. 2017 Oct;7(10):1116-1135. doi: 10.1158/2159-8290.CD-17-0368. Epub 2017 Jun 30.
6
Biliary cancer: Utility of next-generation sequencing for clinical management.
Cancer. 2016 Dec 15;122(24):3838-3847. doi: 10.1002/cncr.30254. Epub 2016 Sep 13.
7
Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.
World J Gastroenterol. 2016 Jul 7;22(25):5814-21. doi: 10.3748/wjg.v22.i25.5814.
9
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.
Oncologist. 2016 May;21(5):594-9. doi: 10.1634/theoncologist.2015-0446. Epub 2016 Mar 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验